What We Do

Discovery & Translational Sciences

Strategy Overview

Print

Our Grand Challenges programs have awarded grants for early-stage research to more than 1,000 innovators in over 50 countries.

Our Goal:

to identify, support, and shape scientific research that can have the most impact and to accelerate the translation of scientific discoveries into solutions that improve people's health and save lives.

The Challenge

At A Glance

Working closely with the foundation’s other global programs, we seek to channel resources into scientific discovery to create more practical versions of existing solutions and develop new solutions where needed.

Our areas of focus include vaccines, drugs, diagnostics, maternal and child health, and control of disease-transmitting mosquitoes.

To speed the translation of scientific discovery into implementable solutions, we seek better ways to evaluate and refine potential interventions before they enter costly and time-consuming late-stage clinical trials.

Through our grant programs, including the Grand Challenges programs, we aim to engage the world’s most innovative researchers and to build a global network of research initiatives and funding partners.

Our Discovery & Translational Sciences strategy is led by Chris Wilson, director, and is part of the foundation’s Global Health Division.

Research and innovation are essential for improving people’s health and saving lives. Vaccines prevent devastating infections and illnesses, drugs help manage and treat disease, and diagnostic tools, medical devices, and other health-related interventions enable providers to anticipate, prevent, diagnose, and manage illness and thereby improve people’s overall health. Increasingly, these tools are yielding significant benefits for the world’s poorest and most vulnerable populations.

But too many health conditions in the developing world still lack effective, appropriate, and affordable solutions. And too little funding is directed toward problems that disproportionately affect the world’s poor. According to some estimates, only 10 percent of all medical research is devoted to conditions that account for 90 percent of the global disease burden. Moreover, due to limited support for research that addresses some of the most neglected diseases and populations, the world’s best scientists are not sufficiently engaged.

We urgently need to develop and implement new strategies to achieve the eradication of polio. We need new vaccines for HIV/AIDS, malaria, and tuberculosis (TB). Treatments for diseases such as TB and malaria are becoming less effective due to drug resistance. Many diagnostic tools are either inadequate or not available in poor communities. Better contraceptives are needed to address the demand for family planning options, as are new, more holistic approaches to ensuring healthy birth, growth, and development.

The Opportunity

While discovery research can increase the likelihood of dramatic progress in tackling persistent global health and development problems, we must ensure that it is focused for maximum impact. We must foster bold innovation and identify and pursue potentially transformative ideas, despite a high risk of failure.

Wireless patches that monitor the vital signs of pregnant women and fetuses could provide an inexpensive way to advance research on preterm birth.

Dramatic progress in global health and development can be made if research institutions, governments, foundations, nongovernmental organizations, and private industry join together to generate new discoveries and new technologies that could greatly improve outcomes for families and children.

To reveal new ways to solve key health problems, we must work together to fill gaps in knowledge about the causes of those problems. From the start of projects, we must consider the path through development and delivery of a solution, anticipating how to test a tool or technology, how to introduce it, and who will use and pay for it. And we must promote cross-discipline collaboration and coordination among researchers and funders to help ensure that solutions are developed that will be sustainable and will have impact at the greatest possible scale.

Our Strategy

Working closely with other global programs at the Bill & Melinda Gates Foundation, the Discovery & Translational Sciences program aims to create and improve preventive, diagnostic, and therapeutic interventions for infectious diseases as well as other conditions that affect mothers, infants, and children. We do this by identifying and filling gaps in scientific knowledge, creating or implementing new technology platforms that can accelerate research in support of our goals, and investing in potentially transformative ideas.

All of our investments advance the goal of creating solutions that can be deployed, accepted, and sustained in the developing world. To speed the translation of scientific discovery into implementable solutions, we seek better ways to evaluate and refine potential interventions—such as vaccine candidates—before they enter costly and time-consuming late-stage clinical trials.

We seek ideas and solutions from creative minds across the globe and from diverse fields, and we invest in discovery research through a variety of mechanisms, including our Grand Challenges grant programs. Together with our Grand Challenges partners, including government agencies and other donor institutions, we work to define areas of urgent need, foster collaboration among researchers, and build a global network of research initiatives and funders.

Areas of Focus

Our efforts fall into four main areas: vaccine discovery, drug discovery, maternal and child health, and control of disease-transmitting mosquitoes.

Vaccine Discovery

A number of problems plague the development of vaccines against infectious diseases, including insufficient quality and diversity of preclinical candidates, slow entry into and limited throughput in early-stage test-of-concept trials in humans, and the high cost of clinical trials. It typically takes 15 to 20 years to go from target discovery to deployment of a new vaccine even when the paradigm is well established, which is not the case for diseases such as HIV, TB, and malaria, for which new approaches are required.

A low-cost microneedle patch for delivering inactivated polio vaccine is in the testing phase.

We invest in technologies that can identify promising vaccine candidates and refine them before they enter costly and time-consuming late-stage clinical trials. We also invest in research to better understand the health factors that affect susceptibility to infectious diseases and vaccine efficacy, such as malnutrition and co-infections. Furthermore, we seek more effective models of collaboration with major vaccine manufacturers to better identify and pursue mutually beneficial opportunities.

Our vaccine discovery efforts focus on developing vaccine technologies and closing knowledge gaps to facilitate the eradication of polio, testing a new strategy for developing next-generation malaria vaccines and transmission-blocking immunotherapeutics, developing a broadly effective HIV/AIDS vaccine, and enabling more rational and accelerated development of TB vaccine candidates.

Drug Discovery

Antimicrobial drugs have been the cornerstone of infectious disease treatment, but relatively few treatment options are available for the diseases that have the greatest impact in the developing world. Drug-resistant TB and malaria are also growing problems.

We work to speed the identification of the best drug candidates, and, as we do with vaccine discovery, we look for opportunities to collaborate with pharmaceutical companies because of their unique resources and expertise and to foster productive academic-industry interactions. We also seek to develop new technologies and approaches to slow the evolution and spread of drug resistance, including alternative formulations and drug-delivery technologies.

We support efforts to create a new generation of more effective and less toxic drugs to treat malaria, TB, visceral leishmaniasis (black fever), human African trypanosomiasis (sleeping sickness), onchocerciasis (river blindness), and lymphatic filariasis (elephantiasis), and to control severe diarrhea.

Maternal and Child Health

A broad range of scientific studies are needed to identify how maternal, fetal, newborn, and infant health outcomes are affected by factors including nutrition, infection, and exposure to environmental toxins.

We invest in research to discover the causes of preterm birth.

We invest in research to discover the causes of preterm birth (PTB), which is a leading cause of infant mortality, and to develop innovative strategies for prevention. Efforts include developing biomarkers for PTB, which can be applied in early pregnancy to predict impending PTB and thereby target use of established preventive measures and treatments. We fund projects to establish metrics for, and discover the causes of, growth faltering in utero and during the first two years of life—a window of time in which serious health problems can impair growth and affect long-term health—and to develop new ways to prevent or reverse unhealthy growth marked by stunting and wasting. Through our Grand Challenges Explorations program and other efforts, we are seeking new approaches to measuring physical growth, brain function, and development in order to better guide and monitor healthy growth interventions.

Controlling Disease-Transmitting Mosquitoes

Mosquitoes spread many serious diseases, including malaria and dengue fever, to millions of people annually. A primary strategy for fighting these diseases is the use of insecticides to kill disease-transmitting mosquitoes. Mosquitoes have grown increasingly resistant to available insecticides, however, and some insecticides are too toxic for widespread use. They also can require people to change their behavior—to use bed nets, for instance—and they need funding to maintain distribution systems.

Our investments in mosquito control include nontraditional biological and genetic approaches as well as new chemical interventions aimed at depleting or incapacitating disease-transmitting mosquito populations. One biological control project for dengue fever that began through our Grand Challenges in Global Health grant program has progressed to field trials in Australia, Indonesia, and Vietnam.

Supporting Programs

Grand Challenges Grant Programs

One way that we spur breakthrough advances in global health and development is through our Grand Challenges grant programs, which aim to engage creative minds across scientific disciplines and across the world—including those who have not traditionally taken part in global health-related research—to seek innovative solutions to specific global health and development challenges.

A device under development by a U.S. company uses microneedles and vacuum suction to safely and painlessly collect blood samples for medical diagnosis.

The Grand Challenges in Global Health program was launched in 2003 to focus on persistent challenges in improving health in the developing world. It began with the award of 45 grants totaling more than US$450 million to scientists in 33 countries. In 2011, we launched new initiatives under the program aimed at discovering biomarkers of health and disease and new ways to achieve healthy birth, growth, and development.

In 2008, we launched Grand Challenges Explorations to encourage even bolder solutions in specific areas. Anyone with a promising idea can apply using a simple two-page online application; no preliminary data is required. Initial grants are for US$100,000, and successful projects have the opportunity to receive a follow-on grant of up to US$1 million.

To date, nearly 800 Grand Challenges Explorations initial grants have been awarded to scientists in 53 countries. Originally focused on global health topics, the program is also being used in new ways by a growing number of foundation teams. New challenge topics include Aid is Working. Tell the World, which is intended to uncover new ways to find and distribute stories that will inspire people to support development aid, and Labor-saving Innovations for Women Smallholder Farmers.

Governments and NGOs around the world are developing their own Grand Challenges programs and committing significant funds, both independently and in partnership with the foundation. For example, the Canadian government has committed CAD$225 million through the not-for-profit organization Grand Challenges Canada to fund global health ideas that integrate scientific, social, and business innovation; the U.S. Agency for International Development (USAID) has launched a series of Grand Challenges for Development programs, the first being Saving Lives at Birth, which includes Grand Challenges Canada and the foundation as partners; and Grand Challenges Brazil was launched in 2012 as a partnership framework between the government of Brazil and the foundation, with the first joint initiative focused on reducing the burden of preterm birth.

Ethical, Social, and Cultural Program

Ethical, social, and cultural considerations are important in all of the foundation’s work. Not only do we strive to be respectful and sensitive to the communities we work with, but we also aim to design our efforts to ensure the greatest chance of acceptance, which is a prerequisite for success.

An international team of biologists is investigating ways to shorten the lifespan of mosquitoes that transmit the dengue virus.

Originally focused on supporting the Grand Challenges in Global Health program, our Ethical, Social, and Cultural (ESC) program now works with program teams across the foundation to anticipate and address cultural barriers to global health and development initiatives. Examples of the ESC program’s recent work include developing community engagement guidelines for TB drug trials, providing guidance for polio-related data sharing, and developing a collaboration model to promote cooperation and trust between public and private groups that work to improve infant and young child nutrition.

Related

Visit Our Blog

Connect